Gabapentin Tablet, Film Coated
Product Images NDC 55154-8193

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 55154-8193). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp50701

Gabapentin 600 mg film-coated oral tablet, oblong and white, imprinted with "ZE" on one side and "72" on the other side of the score line. Labeler is Cardinal Health 107, LLC.*

FDA Label Image

Ahp51801

Gabapentin 600 mg film-coated tablets for oral use, shown as white, oval-shaped tablets scored on one side. One tablet face is embossed with "ZE 71". Labeler is Cardinal Health 107, LLC.*

FDA Label Image

Equation

The image shows the Cockcroft-Gault equation used to estimate creatinine clearance (CLCr) based on age, weight, serum creatinine, with an adjustment factor of 0.85 for female patients. It is a formula involving age in years, weight in kilograms, and serum creatinine in mg/dL.*

FDA Label Image

Figure 1

A line graph depicting mean pain scores over an 8-week period comparing placebo to Gabapentin at 3600 mg/day. The x-axis represents weeks, with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin scores decrease steadily compared to placebo over time.*

FDA Label Image

Figure 2

A line graph showing mean pain scores over 7 weeks for placebo and gabapentin treatment groups at 1800 mg/day and 2400 mg/day doses. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin groups show a greater reduction in pain scores compared to placebo.*

FDA Label Image

Figure 3

A bar chart comparing response percentages between placebo (PBO) and gabapentin (GBP) at different doses in two studies. Study 1 shows 12% for PBO and 29% for GBP 3600 mg. Study 2 shows 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance levels p < 0.01 and p < 0.001 are indicated.*

FDA Label Image

Figure 4

A scatter plot chart showing the difference percentage on the y-axis versus daily dose in mg on the x-axis for Gabapentin. Data points are represented for three studies labeled 'STUDY a', 'STUDY b', and 'STUDY c' with varying symbols and shading. The daily dose ranges from 600 mg to 1800 mg, and the difference percentages vary between approximately 7% and 18%.*

FDA Label Image

Structure

Chemical structure diagram of gabapentin, showing a cyclohexane ring with amine and carboxyl functional groups attached.*

FDA Label Image

Structural Formula (Image 01)

Gabapentin Tablets, USP 600 mg film-coated tablets package label containing 10 tablets. The label includes storage instructions, warnings about child resistance and institutional use, and directions for pharmacists to dispense with a Medication Guide. It lists Cardinal Health 107, LLC as the distributor and American Health Packaging as the packager and distributor location.*

FDA Label Image

Bag Label (Image 02)

Gabapentin Tablets, USP 800 mg, film-coated oral tablets in a unit dose package of 10 tablets. The label includes storage instructions, dosage guidance, a warning that the package is not child resistant and intended for institutional use, and a note for pharmacists to dispense with the Medication Guide. Distributed by Cardinal Health, Dublin, OH, with packaging by American Health Packaging in Columbus, OH.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.